| Patient | Srinivasa Ramanujan |
|---|---|
| Date of birth | 1996-12-22 |
| Identifiers | MRN HR-ET020-SYN; SSN (made up) 000-20-1937 |
| Document date | 2026-02-23 |
| Author | Edmund Ashworth, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six weeks: recovery, final sputum cultures, liver tests before rifampin, vitamin B12, mood, influenza vaccine. [S]
Mr. Ramanujan returns six weeks after diagnosis. He finished paromomycin as planned and his stools returned to normal within two days. He has had no fever, the pain under his ribs has gone, and he has gained almost 3 kg. He is cooking twice a day now, with milk and curd daily, and takes his vitamin B12 and weekly vitamin D. He sees the counselor weekly, calls his family each Sunday, and has been to two community meals with families from the local Tamil association. The final sputum cultures from January show no growth at six weeks; Dr. Raghunathan reviewed them and the plan for latent infection by message. He is working full days again. [S]
| Element | Detail |
|---|---|
| Abscess treatment | Metronidazole and paromomycin completed |
| Sputum cultures | No growth at six weeks |
| Weight | Up nearly 3 kg |
| Mood | PHQ-9 8 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or sweats; appetite good |
| Gastrointestinal | Negative | No abdominal pain; stools normal |
| Respiratory | Negative | No cough |
| Neurological | Negative | No numbness or tingling |
| Psychiatric | Positive | Mood better; still misses his family; no thoughts of self-harm |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metronidazole 250 mg oral tablet, three tablets (750 mg) three times a day with food for 10 days | Three tablets every 8 hours with food for 10 days | Oral route | 2026-01-14 to 2026-01-23 | completed | S |
| Paromomycin 250 mg oral capsule, two capsules (500 mg) three times a day with meals for 7 days, started the day after metronidazole ends | Two capsules every 8 hours with meals for 7 days | Oral route | 2026-01-24 to 2026-01-30 | completed | S |
| Vitamin B12 (cyanocobalamin) 1,000 microgram oral tablet, one tablet daily | One tablet daily | Oral route | 2026-01-14 | active | S |
| Cholecalciferol 50,000 unit (1.25 mg) oral tablet, one tablet once a week for 8 weeks | One tablet once a week for 8 weeks | Oral route | 2026-01-14 to 2026-03-04 | completed | S |
| Rifampin 300 mg oral capsule, two capsules (600 mg) once daily on an empty stomach for 4 months | Two capsules each morning before breakfast for 4 months | Oral route | 2026-02-23 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-02-23 | Body height | 165 | cm | S |
| 2026-02-23 | Body weight | 54.8 | kg | S |
| 2026-02-23 | Body mass index (BMI) [Ratio] | 20.1 | kg/m2 | S |
| 2026-02-23 | Systolic blood pressure | 116 | mm[Hg] | S |
| 2026-02-23 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-02-23 | Heart rate | 74 | /min | S |
| 2026-02-23 | Respiratory rate | 14 | /min | S |
| 2026-02-23 | Body temperature | 36.6 | Cel | S |
| 2026-02-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-02-23 | Leukocytes [#/volume] in Blood by Automated count | 6.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-02-23 | Hemoglobin [Mass/volume] in Blood | 12.6 | g/dL | 13.2-17.1 g/dL | Low | S |
| 2026-02-23 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 94 | fL | 80-100 fL | Normal | S |
| 2026-02-23 | Platelets [#/volume] in Blood by Automated count | 290 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-02-23 | C reactive protein [Mass/volume] in Serum or Plasma | 6 | mg/L | <=5 mg/L | High | S |
| 2026-02-23 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 118 | U/L | 40-129 U/L | Normal | S |
| 2026-02-23 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 7-41 U/L | Normal | S |
| 2026-02-23 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 10-40 U/L | Normal | S |
| 2026-02-23 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-02-23 | Albumin [Mass/volume] in Serum or Plasma | 3.9 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-02-23 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 410 | pg/mL | 232-1245 pg/mL | Normal | S |
| 2026-02-23 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 2026-02-23 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 6 | {score} | S |
Vital signs recorded on 2026-02-23; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; temperature 36.6 °C, pulse 74; weight 54.8 kg |
| Respiratory | Clear, including the right base |
| Abdomen | Liver not enlarged or tender |
| Skin | No jaundice |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Evening fevers to 38.6 °C with night sweats for about four weeks | resolved | confirmed | R50.9 | S — Synthetic presenting symptom, superseded by the diagnosis at the second visit. |
| Weight loss of 5 kg over two months (57 to 52 kg), with poor appetite | resolved | confirmed | R63.4 | S — Synthetic presenting symptom, superseded by the diagnosis at the second visit. |
| Dull right upper quadrant pain for three weeks, worse on deep breathing and lying on the right side, with a tender liver edge | resolved | confirmed | R10.11 | S — Synthetic presenting symptom, superseded by the diagnosis at the second visit. |
| Amebic liver abscess: a single 6.2 x 5.4 cm abscess in the right lobe (segment VII) on ultrasound, Entamoeba histolytica antibody positive, blood cultures negative, years after two episodes of dysentery in India; treated with metronidazole and then paromomycin; synthetic modern diagnosis linked to the hepatic amoebiasis later proposed for his illness | active | confirmed | A06.4 | S — Synthetic modern diagnosis; it does not settle the historical diagnostic conflict (CLM-0010, CLM-0011). |
| Vitamin B12 deficiency from a strict vegetarian diet (B12 168 pg/mL), with anemia (hemoglobin 11.2 g/dL, MCV 99 fL) to which inflammation also contributes | active | confirmed | D51.3 | S — Synthetic finding anchored to his documented diet and the vitamin deficiency later proposed. |
| Vitamin D deficiency (25-hydroxyvitamin D 9 ng/mL) | active | confirmed | E55.9 | S — Synthetic finding anchored to his documented diet and the vitamin deficiency later proposed. |
| Positive interferon-gamma release assay, with chest radiograph and sputum smears and NAAT negative for tuberculosis; cultures pending | resolved | confirmed | R76.12 | S — Synthetic finding, superseded by the diagnosis of latent infection when cultures were negative. |
| Latent tuberculosis infection: positive interferon-gamma release assay, normal lungs on the radiograph, three sputum smears, NAAT and cultures negative; treated with four months of rifampin | active | confirmed | Z22.7 | S — Synthetic modern diagnosis; active tuberculosis was excluded, which does not settle the historical question. |
| Adjustment disorder with depressed mood (PHQ-9 12, no thoughts of self-harm) during a serious illness, far from his wife and family | active | confirmed | F43.21 | S — Synthetic modern diagnosis anchored to his documented loneliness; not a claim about his real mental health. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Temperature, symptoms and abdominal examination (liver tenderness, right lower rib tenderness) | Every visit | Completed today | Afebrile; liver not tender |
| Examination | Weight and BMI | Every visit | Completed today | 54.8 kg, up 2.8 kg since intake |
| Laboratory | Blood count and C-reactive protein | At diagnosis, at the end of the tissue course, then until normal | Completed today | White cells 6.8, hemoglobin 12.6, MCV 94, platelets 290; CRP 6 mg/L |
| Laboratory | Liver tests (alkaline phosphatase, ALT, AST, bilirubin, albumin) | At diagnosis, at the end of therapy, and before and during rifampin | Completed today | Normal, the baseline before rifampin |
| Laboratory | Sputum acid-fast smears, NAAT and mycobacterial cultures | Three samples at baseline; cultures final at 6 to 8 weeks | Completed today | Cultures no growth at six weeks; active tuberculosis excluded |
| Medication safety | Amebicide safety and completion (nausea, metallic taste, numbness on metronidazole; diarrhea on paromomycin; no overlap) | At the start and every visit during treatment | Completed today | Both courses completed without lasting side effects |
| Medication safety | Rifampin safety and adherence (nausea, rash, jaundice, missed doses, drug interactions) | Monthly clinical check; liver tests at baseline and as indicated | Completed today | Started today; interactions reviewed; side effects explained |
| Laboratory | Response to vitamin B12 replacement | Reticulocyte count at 1 week; blood count at about 8 weeks; neurologic examination at diagnosis | Completed today | Hemoglobin 12.6 g/dL and B12 410 pg/mL; blood count again at three months |
| Self-management | Diet and weight plan within his vegetarian rules | Every visit | Completed today | Two meals a day; milk and curd daily |
| Survey | PHQ-9 and GAD-7 | At least monthly while symptoms are active | Completed today | PHQ-9 8, GAD-7 6 |
| Survey | Suicide-risk review, safety plan and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; safety plan current |
| Self-management | Support far from home (counseling, contact with family and community, department and fellowship) | Every visit | Completed today | Weekly counseling, calls home and community meals |
| Medication safety | Influenza vaccine | Each season | Completed today | Given today; deferred at intake because of fever |
| Referral | Infectious diseases review | At diagnosis; then at six weeks for the cultures and latent infection | Completed today | Dr. Raghunathan reviewed the cultures and agreed with rifampin by message |
Goal progress:
Immunizations given today: Influenza vaccine, inactivated, this season [S]
Guideline basis: Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children (2017); Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020 (2020); DPDx: Amebiasis (laboratory diagnosis, including antibody detection in extraintestinal disease) (2026); A Review of the Global Burden, New Diagnostics, and Current Therapeutics for Amebiasis (2018); Position of the Academy of Nutrition and Dietetics: Vegetarian Diets (2016); CMID: Clinical Monitoring Intelligence Database, anemia and depression monographs (2026); Depression and Suicide Risk in Adults: Screening (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); Adult Immunization Schedule by Age (2026)
Follow-up: Monthly clinical check on rifampin; preventive visit in about six weeks. Three-month review with blood count, liver tests, vitamins and mood. Call for jaundice, rash, vomiting, or fever. Next scheduled visit 2026-04-06: periodic adult preventive visit with pre-travel advice. [S]